Repurposing Nucleoside Analogs for Human Coronaviruses

Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified no...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy Jg. 65; H. 1
Hauptverfasser: Zandi, Keivan, Amblard, Franck, Musall, Katie, Downs-Bowen, Jessica, Kleinbard, Ruby, Oo, Adrian, Cao, Dongdong, Liang, Bo, Russell, Olivia O, McBrayer, Tamara, Bassit, Leda, Kim, Baek, Schinazi, Raymond F
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 16.12.2020
Schlagworte:
ISSN:1098-6596, 1098-6596
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1098-6596
1098-6596
DOI:10.1128/AAC.01652-20